rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

RxSight, Inc.

RXST · Nasdaq

Health CareMedical DevicesNot moving yet

RXST stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 23.6% below that average now. Medical Devices: 27% of its 181 stocks in an uptrend (−9 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
27% -9 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$236K
Officials’ trades on record
0
Institutions holding
146 (-9)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

17 Apr – 16 Oct
19%29%40%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1.3M$0$929KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months4
Buyers · sellers0 · 4
WhoDidSharesTraded
Eric WeinbergSee remarkssold2,041at $6.962 Sep 2026filed 2 Sep 2026
Ilya GoldshlegerChief Operating Officersold2,041at $6.962 Sep 2026filed 2 Sep 2026
Mark WilterdingChief Financial Officersold7,765at $6.962 Sep 2026filed 2 Sep 2026
Ronald M. Md KurtzChief Medical Officersold5,100at $6.962 Sep 2026filed 2 Sep 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders146-9 on the quarter
New · exited26 · 36
Reported value$195.7M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 20265,790,408$27.9M+2,603,316+81.7%
MILLENNIUM MANAGEMENT LLCadded · filed 14 Aug 20263,030,287$14.6M+970,828+47.1%
No Street GP LPadded · filed 14 Aug 20262,055,000$9.9M+55,000+2.8%
NOMURA HOLDINGS INCunchanged · filed 14 Aug 20262,000,060$9.6M00.0%
D. E. Shaw & Co., Inc.added · filed 14 Aug 20261,985,215$9.6M+25,483+1.3%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 20261,675,582$8.1M-17,353−1.0%
AQR CAPITAL MANAGEMENT LLCadded · filed 14 Aug 20261,533,826$7.4M+897,697+141.1%
FEDERATED HERMES, INC.added · filed 12 Aug 20261,201,195$5.8M+120,483+11.1%
TWO SIGMA INVESTMENTS, LPreduced · filed 14 Aug 20261,147,048$5.5M-153,212−11.8%
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUNDunchanged · filed 13 Aug 20261,131,400$5.5M00.0%
31 Mar 2023 – 30 Jun 2026
64131197Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Eric Weinberg Company insiderSee remarks · last 15 Sep 20266 · 7
Ilya Goldshleger Company insiderChief Operating Officer · last 5 Sep 20261 · 36
Mark Wilterding Company insiderChief Financial Officer · last 5 Sep 20260 · 1
Ronald M. Kurtz Company insiderChief Medical Officer · last 5 Sep 20262 · 5
Aziz Mottiwala Company insiderPresident and CEO · last 24 Jul 20260 · 0
Bakker Juliet Tammenoms Company insiderDirector · last 17 Jun 20265 · 10
Jesse Anderson Corley Company insiderDirector · last 17 Jun 20266 · 2
Julie Andrews Company insiderDirector · last 17 Jun 20261 · 1
Raymond W. Cohen Company insiderDirector · last 17 Jun 20260 · 0
Robert J. Palmisano Company insiderDirector · last 17 Jun 20260 · 0
Robert Keith Warner Company insiderDirector · last 17 Jun 20261 · 3
Shweta Maniar Company insiderDirector · last 17 Jun 20260 · 5

Same industry

RCEL Avita MedicalLeading+100%
ATRC AtriCureLeading+49%
HAE HaemoneticsLeading+48%
HTFL HeartflowLeading+40%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202576.6%
Operating profit marginFY 2025 · to 31 Dec 2025-35.8%
Free cash flow marginFY 2025 · to 31 Dec 2025-14.4%
Return on capital employedFY 2025 · to 31 Dec 2025-16.9%
Research spendFY 2025 · to 31 Dec 202528.7%
Share count trendFY 2025 · to 18 Feb 20260.1%
Cash and equivalentsFY 2025 · to 31 Dec 2025$19.9M
Free cash flowFY 2025 · to 31 Dec 2025−$19.3M

Analyst forecasts

No analyst forecasts yet.